{"id":279962,"date":"2025-11-24T03:42:29","date_gmt":"2025-11-24T03:42:29","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/279962\/"},"modified":"2025-11-24T03:42:29","modified_gmt":"2025-11-24T03:42:29","slug":"eli-lilly-becomes-first-drugmaker-to-reach-1-trillion-valuation-on-weight-loss-boom","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/279962\/","title":{"rendered":"Eli Lilly becomes first drugmaker to reach $1 trillion valuation on weight-loss boom"},"content":{"rendered":"

Eli Lilly became the first pharmaceutical company in history to reach a $1 trillion market valuation on Friday, a milestone typically reserved for the world\u2019s largest technology giants. <\/p>\n

The stock briefly crossed the threshold in early trading when shares climbed past $1,057.77 before retreating slightly to around $1,050. Even so, the surge underscores how dramatically the company has transformed into the dominant force in the global weight-loss-drug market.<\/p>\n

Lilly\u2019s meteoric rise has been powered by explosive demand for its incretin-based drugs, including Mounjaro for type 2 diabetes and Zepbound for obesity. Together, the two medicines have become the company\u2019s main growth engine. In the most recent quarter, Mounjaro generated $6.52 billion in revenue, up 109% year-over-year, while Zepbound reached $3.59 billion, soaring 184% from the same period last year. Sales of the two drugs now exceed those of Merck\u2019s cancer blockbuster Keytruda, making Lilly the world\u2019s top-selling drugmaker.<\/p>\n

The rapid adoption of Lilly\u2019s treatments has outpaced that of rival Novo Nordisk, whose Wegovy launch in 2021 was slowed by supply shortages. In the U.S., Lilly now holds 57.9% of the incretin drug market, a category that includes Wegovy and Zepbound. Strong clinical data, faster manufacturing scale-up and broader distribution have helped Lilly widen its lead.<\/p>\n

<\/p>\n

2 View gallery <\/p>\n

\"\u05d6\u05e8\u05d9\u05e7\u05ea<\/a>\"\u05d6\u05e8\u05d9\u05e7\u05ea<\/p>\n

Lilly’s Mounjaro weight-loss drug <\/p>\n

(Photo: Shutterstock)<\/p>\n

Investors have taken notice. Lilly shares have gained more than 35% this year and nearly 200% since early 2023, consistently outperforming the broader market. Since the launch of Zepbound in late 2023, the stock has risen more than 75%, compared with a roughly 50% climb in the S&P 500. Lilly now trades at one of the highest valuations in Big Pharma\u2014about 50 times its projected earnings over the next year\u2014reflecting investor conviction that demand for weight-loss drugs will remain robust.<\/p>\n

The company\u2019s pipeline is driving further optimism. Lilly is preparing to launch orforglipron, a highly anticipated oral weight-loss medicine expected to win approval early next year. The firm is also developing next-generation treatments including retatrutide and eloralintide, which could deliver stronger or more diverse results. Analysts estimate the global weight-loss market could surpass $150 billion by 2030, with Lilly and Novo expected to dominate worldwide sales.<\/p>\n

Lilly\u2019s momentum has also been helped by a recent agreement with the Trump administration that opens Medicare coverage to its weight-loss drugs in exchange for lower cash-pay pricing\u2014potentially adding tens of millions of eligible patients.<\/p>\n

As health-care stocks broadly outperform the market, Lilly now sits in rarified air, standing alongside the likes of Nvidia, Microsoft and Berkshire Hathaway\u2014proof that the weight-loss revolution has reshaped not just medicine, but the upper ranks of corporate America.<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly became the first pharmaceutical company in history to reach a $1 trillion market valuation on Friday,…\n","protected":false},"author":2,"featured_media":279963,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[102,2960,56,54,55],"class_list":{"0":"post-279962","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-health","9":"tag-healthcare","10":"tag-uk","11":"tag-united-kingdom","12":"tag-unitedkingdom"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/279962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=279962"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/279962\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/279963"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=279962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=279962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=279962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}